Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis- related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products used in the collection and processing of blood components, as well as in transfusion medicine. The Fresenius Helios segment operates 111 hospitals with approximately 35,000 beds, such as 88 acute care hospitals and 23 post-acute care clinics; 4 post-acute care centers; 17 prevention centers; and 12 nursing homes. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone49-6172-6080
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$38.28 billion
Profitability
Miscellaneous
Employees273,249
OptionableNot Optionable
FRESENIUS SE &/S (OTCMKTS:FSNUY) Frequently Asked Questions
What is FRESENIUS SE &/S's stock symbol?
FRESENIUS SE &/S trades on the OTCMKTS under the ticker symbol "FSNUY."
How were FRESENIUS SE &/S's earnings last quarter?
FRESENIUS SE &/S (OTCMKTS:FSNUY) posted its earnings results on Wednesday, October, 31st. The company reported $0.23 earnings per share (EPS) for the quarter. The business had revenue of $9.52 billion for the quarter. FRESENIUS SE &/S had a net margin of 5.91% and a return on equity of 12.53%. View FRESENIUS SE &/S's Earnings History.
When is FRESENIUS SE &/S's next earnings date?
What is the consensus analysts' recommendation for FRESENIUS SE &/S?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FRESENIUS SE &/S in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for FRESENIUS SE &/S.
Has FRESENIUS SE &/S been receiving favorable news coverage?
Media headlines about FSNUY stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. FRESENIUS SE &/S earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
Who are some of FRESENIUS SE &/S's key competitors?
Some companies that are related to FRESENIUS SE &/S include Becton Dickinson and (BDX), Stryker (SYK), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), ABIOMED (ABMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), ICU Medical (ICUI), Penumbra (PEN), Insulet (PODD), Globus Medical (GMED) and Novocure (NVCR).
Who are FRESENIUS SE &/S's key executives?
FRESENIUS SE &/S's management team includes the folowing people:
- Mr. Stephan Sturm, CEO & Chairman of Management Board - Fresenius Management SE (Age 55)
- Ms. Rachel Clare Empey, CFO & Member of Management Board - Fresenius Management SE (Age 42)
- Dr. Francesco De Meo, Member of Management Board - Fresenius Management SE (Age 54)
- Dr. Jürgen Götz, Chief Legal & Compliance Officer & Labor Relations Director and Member of Management Board - GP (Age 54)
- Dr. Ernst Wastler, Member of Management Board - Fresenius Management SE (Age 59)
How do I buy shares of FRESENIUS SE &/S?
Shares of FSNUY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is FRESENIUS SE &/S's stock price today?
One share of FSNUY stock can currently be purchased for approximately $12.55.
How big of a company is FRESENIUS SE &/S?
FRESENIUS SE &/S has a market capitalization of $27.07 billion and generates $38.28 billion in revenue each year. The company earns $2.05 billion in net income (profit) each year or $0.92 on an earnings per share basis. FRESENIUS SE &/S employs 273,249 workers across the globe.
What is FRESENIUS SE &/S's official website?
How can I contact FRESENIUS SE &/S?
FRESENIUS SE &/S's mailing address is Else-Kroner-Stra¿e 1, Bad Homburg 2M, 61352. The company can be reached via phone at 49-6172-6080 or via email at [email protected]
MarketBeat Community Rating for FRESENIUS SE &/S (OTCMKTS FSNUY)
MarketBeat's community ratings are surveys of what our community members think about FRESENIUS SE &/S and other stocks. Vote "Outperform" if you believe FSNUY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FSNUY will underperform the S&P 500 over the long term. You may vote once every thirty days.
